New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
December 06, 2024 01:15 ET
|
Novartis Pharma AG
In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average hemoglobin (Hb) level versus baseline in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were...
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
November 27, 2024 01:15 ET
|
Novartis Pharma AG
Approval is based on Phase III NATALEE data showing Kisqali® (ribociclib) plus adjuvant endocrine therapy (ET) demonstrated clinically meaningful invasive disease-free survival (iDFS) benefit in...
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
October 26, 2024 19:50 ET
|
Novartis Pharma AG
New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of...
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
October 18, 2024 06:47 ET
|
Novartis Pharma AG
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment...
Revolution in the lab powered by DIAGU Ltd: How AI is reshaping diagnostic testing for faster, smarter healthcare
May 14, 2024 12:13 ET
|
Diagu LTD.
Halesowen, UK, May 14, 2024 (GLOBE NEWSWIRE) -- This display of AI-driven GetLabTest.com technology exemplifies the next generation of diagnostics, delivering unprecedented accuracy and speed in...
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
Hint Announces Partnership with E Powered Benefits to Enable Better Access to Direct Primary Care Through Performance Health Plans
January 11, 2024 10:00 ET
|
Hint Health
San Francisco, CA, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Hint Health, the leading provider of membership management, billing, and employer direct contracting infrastructure for Direct Primary Care (DPC)...
Sandoz presents compelling investment proposition as standalone company at Capital Markets Day
June 08, 2023 01:15 ET
|
Novartis Pharma AG
Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to further...
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event
September 22, 2022 01:15 ET
|
Novartis Pharma AG
Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight...
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
June 22, 2022 20:01 ET
|
Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...